Literature DB >> 16808915

Matrix metalloproteinases--a conceptional alternative for disease-modifying strategies in ALS/MND?

Albert C Ludolph1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808915     DOI: 10.1016/j.expneurol.2006.05.013

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  4 in total

1.  Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Authors:  Albert C Ludolph; Sarah Jesse
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  Metalloproteinase alterations in the bone marrow of ALS patients.

Authors:  Patrizia Bossolasco; Lidia Cova; Cinzia Calzarossa; Federica Servida; Niccolò Emanuele Mencacci; Francesco Onida; Elio Polli; Giorgio Lambertenghi Deliliers; Vincenzo Silani
Journal:  J Mol Med (Berl)       Date:  2010-01-21       Impact factor: 4.599

Review 3.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Agnieszka Słowik
Journal:  J Neural Transm (Vienna)       Date:  2014-07-22       Impact factor: 3.575

Review 4.  Amyotrophic lateral sclerosis: applications of stem cells - an update.

Authors:  Lidia Cova; Vincenzo Silani
Journal:  Stem Cells Cloning       Date:  2010-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.